Bicara Therapeutics Inc. Common Stock
BCAX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $507 | $710 | $948 |
| - Cash | $172 | $437 | $462 | $490 |
| + Debt | $1 | $2 | $1 | $1 |
| Enterprise Value | – | $72 | $248 | $459 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$36 | -$32 | -$42 | -$27 |
| % Margin | – | – | – | – |
| Net Income | -$36 | -$27 | -$37 | -$21 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.67 | -0.5 | -0.68 | -0.38 |
| % Growth | -34% | 26.5% | -78.9% | – |
| Operating Cash Flow | -$29 | -$26 | -$28 | -$30 |
| Capital Expenditures | -$0 | $0 | $0 | -$0 |
| Free Cash Flow | -$29 | -$26 | -$28 | -$30 |